Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection
Elisabetta Degasperi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Pietro Lampertico(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Marta Borghi(University of Milan), Roberta D’Ambrosio(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alessio Aghemo, G. Lunghi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Massimo Iavarone(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), R. Soffredini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Massimo Colombo(IRCCS Humanitas Research Hospital), Angelo Sangiovanni(Ospedale Maggiore)
Cited by 114
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
The natural history of compensated cirrhosis due to hepatitis C virus
|Hepatology|2006|631
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance☆
|Gastroenterology|2004|607
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539